Rapport Therapeutics (RAPP) Current Assets (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Current Assets of $484.7 million for Q1 2026, up 66.58% year-over-year from $291.0 million in Q1 2025, and down 2.78% quarter-over-quarter from $498.6 million in Q4 2025.
Rapport Therapeutics (RAPP) Current Assets (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Current Assets for 4 consecutive years, with $484.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 66.58% year-over-year to $484.7 million; the TTM figure through Mar 2026 stood at $484.7 million (up 66.58% YoY), while the FY2025 annual figure was $498.6 million, up 60.93% from the prior year.
- Current Assets retreated to $484.7 million in Q1 2026 per RAPP's latest filing, from $498.6 million in the prior quarter.
- Across five years, Current Assets topped out at $520.7 million in Q3 2025 and bottomed at $150.9 million in Q4 2023.
- Historically, Current Assets has averaged $354.7 million across 4 years, with a median of $325.9 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets soared 105.34% — and 2025, when it declined 20.67%.
- Rapport Therapeutics' Current Assets stood at $150.9 million in 2023, then soared by 105.34% to $309.8 million in 2024, then surged by 60.93% to $498.6 million in 2025, then fell by 2.78% to $484.7 million in 2026.
- Business Quant data shows RAPP's Current Assets at $484.7 million in Q1 2026, $498.6 million in Q4 2025, and $520.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 446.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 446.86 Mn |
| Mar 31, 2026 | 484.70 Mn |
| Dec 31, 2025 | 498.56 Mn |
| Sep 30, 2025 | 520.66 Mn |
| Jun 30, 2025 | 270.24 Mn |
| Mar 31, 2025 | 290.97 Mn |
| Dec 31, 2024 | 309.80 Mn |
| Sep 30, 2024 | 325.94 Mn |
| Jun 30, 2024 | 340.67 Mn |
| Dec 31, 2023 | 150.87 Mn |